Clinical Trial Update: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates a T cell receptor-engineered T cell therapy targeting KRAS mutations in patients with advanced solid tumors and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KRAS-targeted TCR-T cell therapy

Snippet

Sponsor: Ting Deng | Conditions: Tumor, Solid | Phase 1 | Status: RECRUITING